REGULUS THER.COMPAR DL001
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more
Market Cap & Net Worth: REGULUS THER.COMPAR DL001 (7RG0)
REGULUS THER.COMPAR DL001 (F:7RG0) has a market capitalization of $497.47 Million (€484.64 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #11202 globally and #1206 in its home market, demonstrating a -0.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying REGULUS THER.COMPAR DL001's stock price €7.00 by its total outstanding shares 69234096 (69.23 Million).
REGULUS THER.COMPAR DL001 Market Cap History: 2015 to 2025
REGULUS THER.COMPAR DL001's market capitalization history from 2015 to 2025. Data shows change from $72.70 Billion to $497.47 Million (-38.22% CAGR).
REGULUS THER.COMPAR DL001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how REGULUS THER.COMPAR DL001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 7RG0 by Market Capitalization
Companies near REGULUS THER.COMPAR DL001 in the global market cap rankings as of March 18, 2026.
Key companies related to REGULUS THER.COMPAR DL001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
REGULUS THER.COMPAR DL001 Historical Marketcap From 2015 to 2025
Between 2015 and today, REGULUS THER.COMPAR DL001's market cap moved from $72.70 Billion to $ 497.47 Million, with a yearly change of -38.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €497.47 Million | +386.11% |
| 2024 | €102.34 Million | +28.57% |
| 2023 | €79.59 Million | -10.40% |
| 2022 | €88.83 Million | -51.55% |
| 2021 | €183.35 Million | -74.46% |
| 2020 | €717.78 Million | +42.25% |
| 2019 | €504.57 Million | -23.16% |
| 2018 | €656.66 Million | -90.80% |
| 2017 | €7.14 Billion | -61.36% |
| 2016 | €18.47 Billion | -74.59% |
| 2015 | €72.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of REGULUS THER.COMPAR DL001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $497.47 Million USD |
| MoneyControl | $497.47 Million USD |
| MarketWatch | $497.47 Million USD |
| marketcap.company | $497.47 Million USD |
| Reuters | $497.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.